| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.9 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |